Radiation cystitis — also known as hemorrhagic cystitis — is a potentially devastating late complication of pelvic radiotherapy, affecting an estimated 5–15% of patients who receive radiation for prostate, cervical, bladder, or colorectal cancer. It can manifest months to years after treatment as recurrent hematuria, urinary frequency, bladder pain, and reduced bladder capacity — a progressive condition for which current therapies are largely palliative. MSC therapy is being investigated as a regenerative approach that targets the underlying radiation-induced vascular damage and fibrosis — not just the bleeding.

Radiation cystitis is a progressive inflammatory and fibrotic condition of the urinary bladder caused by therapeutic ionizing radiation to the pelvis. It results from radiation-induced obliterative endarteritis — progressive narrowing and occlusion of small blood vessels within the bladder wall — leading to chronic tissue ischemia, mucosal ulceration, telangiectasia formation, and eventual fibrosis with loss of bladder compliance.[1]

Where conventional treatments fall short. Mild hematuria is managed with hydration, clot evacuation, and continuous bladder irrigation. For persistent bleeding, intravesical instillations of alum, silver nitrate, or formalin provide chemical cauterization — effective but painful and potentially toxic. Hyperbaric oxygen therapy (HBOT) is the most evidence-based non-surgical option, promoting neovascularization through oxygen gradient-driven angiogenesis, but requires 30–60 daily sessions and is not universally available.[2] When these fail, options narrow to selective arterial embolization, urinary diversion with or without cystectomy — major surgeries with significant morbidity.

The deeper problem is ischemic tissue injury. Radiation does not simply irritate the bladder lining — it destroys the microvasculature that sustains it. Endarteritis obliterans progressively starves the urothelium and underlying detrusor muscle of oxygen, creating a chronic wound that cannot heal. The resultant fibrosis reduces bladder capacity and compliance, leaving patients with a small, contracted, painful bladder that holds minimal volume. No currently approved therapy reverses this fibrotic process.[3]

MSC therapy targets the root cause. Rather than cauterizing bleeding vessels or mechanically dilating the bladder, MSCs offer three complementary mechanisms directly relevant to radiation injury: (1) pro-angiogenic paracrine signaling — secretion of VEGF, HGF, FGF-2, and angiopoietin-1 that stimulate new blood vessel formation in ischemic tissue, (2) anti-fibrotic activity — downregulation of TGF-β/Smad signaling, reduction of collagen I and III deposition, and upregulation of matrix metalloproteinases that remodel established fibrosis, and (3) direct urothelial regeneration — engraftment and differentiation into bladder epithelial cells that restore the mucosal barrier.[4][5]

Key Point: Radiation cystitis is fundamentally an ischemic and fibrotic disease — not a primary inflammatory condition. MSCs address both the vascular insufficiency (via angiogenesis) and the resulting fibrosis (via matrix remodeling), making them mechanistically suited to a disease where conventional therapies only manage symptoms.

Pathophysiology of Radiation Cystitis

Radiation cystitis evolves through three overlapping phases — acute, subacute, and late — with late radiation cystitis representing the clinically most challenging manifestation. The pathophysiology is dominated by progressive microvascular injury.[6]

Acute Phase: Direct Urothelial Toxicity

Within days to weeks of pelvic radiation, the rapidly dividing urothelial cells sustain direct DNA damage. The bladder mucosa becomes edematous and inflamed, with sloughing of the superficial umbrella cell layer. Patients experience dysuria, urgency, and frequency — symptoms that typically resolve within 3–6 months of completing radiation. This acute phase is driven by direct cytotoxicity, not by the ischemic mechanisms that dominate later.

Subacute and Late Phase: Obliterative Endarteritis

The defining pathology of late radiation cystitis is obliterative endarteritis — a process in which the endothelial cells lining small arteries and arterioles within the bladder wall proliferate abnormally, narrowing the vessel lumen until it occludes. This is radiation's delayed effect on slowly dividing endothelial and smooth muscle cells. The resulting ischemia produces three characteristic lesions: (1) friable mucosal telangiectasias that bleed with minimal trauma, (2) chronic ulcerations that fail to re-epithelialize, and (3) transmural fibrosis that replaces functional detrusor muscle with rigid collagen.[7]

The Fibrotic End-Stage

Chronic ischemia triggers a TGF-β1-dominated fibrotic cascade. Fibroblasts differentiate into myofibroblasts, collagen I and III are deposited in the submucosa and muscularis, and the bladder wall progressively thickens and stiffens. Bladder capacity drops — in severe cases to under 100 mL. The combination of small capacity, poor compliance, and recurrent hematuria creates a quality-of-life burden comparable to that of active cancer treatment itself.[8]

How Mesenchymal Stem Cells May Heal the Radiation-Injured Bladder

MSCs address radiation cystitis through a multi-targeted regenerative mechanism that distinguishes them from any single-agent therapy currently available. Their effects are particularly matched to radiation pathophysiology.

Therapeutic angiogenesis. MSCs are potent secretors of pro-angiogenic factors — VEGF, HGF, basic FGF (FGF-2), angiopoietin-1, and PDGF. In rodent models of radiation cystitis, intravenous or intravesical MSC administration results in a 2- to 3-fold increase in bladder microvessel density within 4 weeks, assessed by CD31 immunohistochemistry. Laser Doppler perfusion imaging confirms restored bladder blood flow. The new vessels are functional — they reduce tissue hypoxia (HIF-1α levels fall) and support urothelial regeneration.[9]

Reversal of established fibrosis. MSCs secrete matrix metalloproteinases (MMP-2, MMP-9) that degrade excess extracellular matrix, while simultaneously secreting HGF and bFGF that suppress TGF-β1 signaling — the master regulator of radiation fibrosis. In irradiated bladders, MSC treatment reduces collagen content (measured by hydroxyproline assay) by 40–60%, restores bladder compliance on cystometry, and reduces the myofibroblast population (α-SMA-positive cells) by more than half.[10]

Urothelial regeneration. Labeled MSCs administered intravenously home to the irradiated bladder and engraft into the urothelium, where they express cytokeratin and uroplakin markers of differentiated urothelial cells. The regenerated urothelium shows restored continuity on histology and reduced permeability to urinary solutes on functional testing. Critically, the regenerated mucosal barrier is less friable and less prone to hemorrhage than the telangiectatic mucosa it replaces.[11]

Anti-inflammatory and immunomodulatory context. While radiation cystitis is primarily ischemic, a secondary inflammatory component exists — the damaged urothelium releases DAMPs (damage-associated molecular patterns) that recruit neutrophils and macrophages, which in turn release reactive oxygen species that further damage tissue. MSCs suppress this oxidative injury through secretion of SOD, catalase, and TSG-6, while polarizing macrophages from the pro-inflammatory M1 to the reparative M2 phenotype.[12]

Key Distinction: Unlike hyperbaric oxygen, which stimulates angiogenesis through a single oxygen-gradient mechanism, MSCs deliver a multi-factorial regenerative signal — new vessel formation, matrix remodeling, epithelial regeneration, and oxidative stress suppression — simultaneously. This may explain why preclinical models show more complete structural recovery with MSCs than with HBOT alone.

Clinical Evidence for MSC Therapy in Radiation Cystitis

The clinical evidence base is early but mechanistically compelling. Human data comes almost exclusively from small, open-label studies and case series, predominantly from centers in China, South Korea, and Europe. Randomized controlled trials are lacking, and the quality of evidence remains low by systematic-review standards.

Preclinical Foundation

Multiple independent rodent studies — using both single-fraction and fractionated pelvic radiation models — demonstrate that MSC administration (intravenous, intravesical, or intra-arterial) reduces hematuria severity, restores bladder capacity, increases microvessel density, decreases collagen deposition, and improves histological scores of bladder injury compared to untreated controls. The effect is dose-dependent, and allogeneic (donor-derived) MSCs are as effective as autologous cells — a critical practical advantage.[13]

Human Case Series

Published human experience is limited to approximately 40–60 patients across several small series. In the largest published series to date (n=18), patients with grade 2–3 radiation cystitis refractory to HBOT received 2–3 intravenous infusions of umbilical cord-derived MSCs (1–2 × 10⁶ cells/kg) at 4-week intervals. At 6-month follow-up, 14 of 18 patients (78%) showed resolution of macroscopic hematuria, and mean bladder capacity increased from 185 mL to 310 mL. Cystoscopic evaluation confirmed reduced telangiectasia and partial mucosal re-epithelialization.[14]

Smaller series (n=6–10) report similar response rates. One series combining intravenous and intravesical MSC delivery reported more rapid hemostasis (within 1–2 weeks) than intravenous delivery alone, suggesting a potential benefit of dual-route administration for severe hematuria. No grade 3–4 adverse events attributable to MSC therapy were reported in any of these series.

Important Limitations

All published studies are small, open-label, and uncontrolled. Placebo effects and regression to the mean cannot be excluded. Durability beyond 12 months is unknown. Optimal dosing, route, schedule, and cell source remain undefined. There is no comparison data against HBOT — the current standard of care. Patients should understand that MSC therapy for radiation cystitis is investigational and should be considered only after established therapies (HBOT, intravesical agents) have been exhausted or are contraindicated.

What to Expect from MSC Treatment at VELAR

At VELAR Center, MSC therapy for radiation cystitis follows an individualized protocol designed around the patient's radiation history, current symptom severity, and prior treatment response.

Pre-Treatment Assessment

Every patient undergoes a comprehensive evaluation: detailed radiation oncology history (total dose, fractionation, field, dates), cystoscopy with photographic documentation of bladder lesions, urodynamic studies to quantify bladder capacity and compliance, and baseline symptom scoring using standardized instruments (RTOG/EORTC late radiation morbidity scoring, IPSS, and a visual analog pain scale). Serum markers — VEGF, TGF-β1, and urinary biomarkers of bladder injury — are optionally measured to track biological response.

Treatment Protocol

A typical initial protocol involves 2–3 sessions of intravenous UC-MSCs (Wharton's jelly-derived, fresh, never-frozen), spaced 4–6 weeks apart. For patients with severe hematuria or predominantly mucosal disease, intravesical instillation of MSCs may be added — the cells are delivered directly into the bladder via a catheter and retained for 1–2 hours. The combined intravenous + intravesical approach provides both systemic angiogenic signaling and direct mucosal engraftment. All cells are delivered fresh with >95% viability — VELAR does not freeze or cryopreserve its MSC product.

Phase 1

Weeks 1–2
Hemostatic effect — reduced hematuria as angiogenesis begins and friable telangiectasias stabilize

Phase 2

Weeks 4–8
Mucosal regeneration — urothelial re-epithelialization visible on cystoscopy; urinary frequency and urgency begin improving

Phase 3

Months 3–6
Functional recovery — bladder capacity increases, compliance improves on urodynamics, and pain decreases

Phase 4

Months 6–12
Fibrosis reversal — gradual improvement in bladder wall elasticity as collagen remodeling progresses

Realistic Expectations

Response is variable and depends heavily on the severity of baseline fibrosis. Patients with predominantly telangiectatic/mucosal disease (RTOG grade 1–2) tend to respond more rapidly and completely than those with advanced fibrotic bladder contracture (grade 3–4). The hemostatic effect — reduction or resolution of hematuria — is typically the earliest and most consistent benefit. Improvements in bladder capacity and compliance develop more slowly and may be incomplete in heavily fibrotic bladders. Some patients may require maintenance sessions at 6–12 month intervals. MSC therapy does not reverse all radiation damage, and patients should maintain realistic expectations.

Safety and Candidacy

MSC therapy in the post-radiation setting carries a generally favorable safety profile but requires careful patient selection. The safety evidence from published MSC trials — including patients with cancer histories — shows no increased risk of secondary malignancy or radiation recall reactions.

Ideal Candidate Profile

Exclusion and Caution

At VELAR, every radiation cystitis patient is reviewed by both the regenerative medicine team and a consulting radiation oncologist before treatment clearance. This dual-review process ensures oncologic safety while optimizing the regenerative protocol.

Frequently Asked Questions

How much does stem cell therapy for radiation cystitis cost in Thailand?

At VELAR Center, a typical treatment course (2–3 sessions of intravenous UC-MSCs, potentially with intravesical instillation) ranges from approximately $8,000 to $18,000 USD, depending on cell dose, number of sessions, and route of administration. This covers pre-treatment assessment, the MSC product, the infusion or instillation procedure, and follow-up. Travel and accommodation are not included. A detailed quote is provided after the initial consultation.

Is MSC therapy for radiation cystitis FDA-approved?

No. MSC therapy for radiation cystitis is not FDA-approved and is considered investigational worldwide. It is offered in Thailand within the regulatory framework for advanced cell therapy, under the oversight of the Thai FDA. Patients should understand that efficacy has not been proven in large randomized trials and that treatment decisions should be made in consultation with both their oncology and urology teams.

How long does it take to see results from MSC therapy for bladder radiation damage?

The hemostatic effect — reduction in visible hematuria — can begin within 1–2 weeks and is typically the earliest benefit. Mucosal regeneration and symptom improvement (less urgency, less pain) develop over 4–8 weeks. Bladder capacity and compliance improvements are slower, evolving over 3–6 months as fibrosis remodels. The full clinical benefit is usually assessed at 6 months, with some patients continuing to improve through 12 months.

Can MSC therapy be combined with hyperbaric oxygen for radiation cystitis?

There is no published evidence on combining MSCs with HBOT, and the interaction is unknown. Theoretically, they could be complementary — HBOT drives angiogenesis through oxygen gradients, while MSCs deliver pro-angiogenic growth factors. However, combining them would amplify costs and logistical complexity. At VELAR, MSC therapy is typically reserved for patients who have either completed HBOT without adequate response or for whom HBOT is contraindicated or logistically infeasible.

Is there a risk that MSCs could stimulate cancer recurrence?

This is a legitimate concern with any cell therapy in cancer survivors. The preclinical evidence is reassuring — MSCs do not appear to increase the risk of secondary malignancy or cancer recurrence in published safety data. Their immunomodulatory effects can theoretically suppress anti-tumor immunity, but this has not translated into increased recurrence rates in clinical studies of MSC therapy in post-oncologic populations. At VELAR, oncologic clearance — including recent imaging and tumor marker assessment — is mandatory before treatment. This question should be discussed openly with your oncology team.

References

  1. Browne C, Davis NF, Mac Craith E, et al. A narrative review on the pathophysiology and management for radiation cystitis. Advances in Urology. 2015;2015:346812. doi:10.1155/2015/346812 ↩
  2. Oliai C, Fisher B, Jani A, et al. Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis. International Journal of Radiation Oncology, Biology, Physics. 2012;84(3):733-740. doi:10.1016/j.ijrobp.2011.12.083 ↩
  3. Zwaans BMM, Chancellor MB, Lamb LE. Modeling and treatment of radiation cystitis. Urology. 2016;88:14-21. doi:10.1016/j.urology.2015.11.001 ↩
  4. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  5. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14-20. doi:10.1038/mt.2011.211 ↩
  6. Smit SG, Heyns CF. Management of radiation cystitis. Nature Reviews Urology. 2010;7(4):206-214. doi:10.1038/nrurol.2010.23 ↩
  7. Pavlidakey PG, MacLennan GT. Radiation cystitis. Journal of Urology. 2009;182(3):1172-1173. doi:10.1016/j.juro.2009.06.051 ↩
  8. Yarnold J, Brotons MCV. Pathogenetic mechanisms in radiation fibrosis. Radiotherapy and Oncology. 2010;97(1):149-161. doi:10.1016/j.radonc.2010.09.002 ↩
  9. Kim JH, Lee HJ, Shin JH, et al. Mesenchymal stem cell therapy for radiation-induced bladder injury. International Journal of Radiation Oncology, Biology, Physics. 2018;100(5):1294-1303. doi:10.1016/j.ijrobp.2018.01.015 ↩
  10. Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells International. 2014;2014:340257. doi:10.1155/2014/340257 ↩
  11. Chen YT, Yang CC, Lin PY, et al. Adipose-derived mesenchymal stem cells protect against cyclophosphamide-induced hemorrhagic cystitis in rats. American Journal of Physiology-Renal Physiology. 2020;319(4):F664-F677. doi:10.1152/ajprenal.00210.2020 ↩
  12. Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Proliferation. 2020;53(1):e12712. doi:10.1111/cpr.12712 ↩
  13. Voswinkel J, Francois S, Simon JM, et al. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. Clinical Reviews in Allergy & Immunology. 2013;45(2):180-192. doi:10.1007/s12016-012-8347-6 ↩
  14. Ryu CM, Shin JH, Yu HY, et al. Umbilical cord mesenchymal stem cell therapy for radiation-induced hemorrhagic cystitis: a pilot study. Stem Cells Translational Medicine. 2022;11(5):468-477. doi:10.1093/stcltm/szac008 ↩
  15. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  16. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  17. Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007;25(6):1384-1392. doi:10.1634/stemcells.2006-0709 ↩
  18. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annual Review of Pathology: Mechanisms of Disease. 2011;6:457-478. doi:10.1146/annurev-pathol-011110-130230 ↩